Key statistics
On Tuesday, BridgeBio Pharma Inc (BBIO:NSQ) closed at 46.96, -3.54% below its 52-week high of 48.68, set on Jul 14, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 48.19 |
---|---|
High | 48.42 |
Low | 46.63 |
Bid | 46.50 |
Offer | 48.01 |
Previous close | 47.69 |
Average volume | 2.84m |
---|---|
Shares outstanding | 189.88m |
Free float | 153.53m |
P/E (TTM) | -- |
Market cap | 9.06bn USD |
EPS (TTM) | -3.53 USD |
Data delayed at least 15 minutes, as of Jul 15 2025 21:00 BST.
More ▼
- BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
- BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
- BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
- Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
- Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
- BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
- BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
- BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
More ▼